KING’S COLLEGE LONDON (UK)—New developments using protein therapeutics and cell therapy may help prevent organ rejection and extend lives.
The work using protein therapeutics aims to reduce the risk of an organ being damaged in the hours and days following a transplant, by maintaining the quality of the donor organ prior to transplantation.
Currently, organs cannot survive outside the body for more than around 24 hours. In daily life when an infection or virus meets cells or fluids in the body, it activates a part of the immune system, known as the ‘complement’ system, which attacks and attempts to destroy the cells of the intruder organism.
The complement system is usually kept in check by ‘regulators’ which are found on the surface of the cells. Their presence prevents it from attacking the body’s own cells.
However, when an organ is removed for transplantation, complement regulators are lost from the surface of cells due to the lack of blood flow and consequent lack of oxygen.
Unregulated, the complement system begins to attack the organ’s own cells, severely damaging it. Once the transplant is complete, the effect can be amplified as the complement system supports the recipient’s own blood cells in its attack on the organ—resulting in organ rejection.
Scientists have evolved a method for coating the inner surface of donor kidneys with a protective layer made from a substance which is a natural regulator of these proteins in humans.
“We have engineered a protein Mirococept to combat organ damage during transit outside the human body and immediately after transplantation,” says Richard Smith, director of protein therapeutics at the Medical Research Council (MRC) Centre for Transplantation at King’s College London.
“It is an artificial replacement for complement regulators. If enough Mirococept proteins reach the organ’s cell membranes, it can prevent the complement cascade from starting and increases the number of donor organs suitable for transplantation.”
It is hoped this research will help alleviate the clear imbalance between supply and demand of donor organs for transplantation.
According to NHS Blood and Transplant, at 31 March 2010, there were 7,183 patients waiting for a kidney transplant in the UK, and 2,694 kidney transplant operations were performed during the year 2009-10.
Smith and his team have also introduced the ‘tail’ in Mirococept which is specifically designed to latch on to cell walls.
“When we are preparing an organ for transplant we wash it in a solution, and the risk is that the protein will be washed off the organ. The ‘tail’ we have developed snags onto the cell surface and holds it there.
“Imagine the difference between throwing a bucket of water at a wall and throwing a bucket of paint, the water will run off but the paint will stick. This technique, known as tethering, not only enables the protein Mirococept to reach particular types of cells, but also gives it a much better chance of staying there.”
A pilot scale clinical study of 16 kidney transplant patients shows the tethering technique is clinically feasible and safe. The next step is large-scale clinical trials to test whether the method has clinical benefits for patients undergoing organ transplants.
Scientists at King’s College London are also researching cell therapy to improve the longevity of a transplant using white blood cell—regulatory T cells found in healthy individuals—as treatment to prevent an immune system from becoming overactive and rejecting a donated organ.
Currently, transplant recipients have to stick to a strict regimen of potent drugs that pacify the immune system and hopefully prevent rejection of the donated organ.
However, because these drugs suppress the immune system, they may also bring serious health complications, such as infections and some types of cancer.
“Animal studies have already shown that these cells can effectively prevent a transplant being rejected,” says Giovanna Lombardi, professor of human transplant immunology.
“We are currently identifying ways to “grow” these cells from the blood of healthy individuals in the laboratory without them losing their ability to suppress other immune cells and are carrying out a study of the number and quality of regulatory T cells from patients on the waiting list for a kidney transplant.
“We are optimistic that we will be able to carry out the first clinical trials in transplant patients in the next few years.”
It is expected that any clinical trials would involve the isolation and expansion of these cells. The cells would be taken from a patient, multiplied in the laboratory into the numbers of cells needed, and reintroduced into the patients themselves.
More news from King’s College London: www.kcl.ac.uk/news/